Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as ...
Detailed price information for Can-Fite Biopharma Ltd ADR (CANF-A) from The Globe and Mail including charting and trades.
Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for ...
Interim analysis to be conducted under an FDA- and EMA-agreed protocolRamat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma ...
Add Yahoo as a preferred source to see more of our stories on Google. The deals, both announced today, are part of an 18-month string of acquisitions in which the parent of social media app Triller ...
London, UK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- The FITE team proudly announces the launch of their groundbreaking platform in the Centralized Finance (CeFi) arena, named FITE—an acronym for "First In ...
TrillerNet Acquires Premier Live Event and PPV, SVOD, AVOD, and Streaming Platform FITE, Taking Major Next Step in Building Global Content Ecosystem. Will Use FITE's Platform to Expand Triller Fight ...
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address ...
Multiple countries are approving Can-Fite BioPharma Ltd. CANF CFBI ’s Namodenoson for compassionate use in patients with advanced liver cancer. These countries, including Romania and Israel, seem to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results